ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to…
#Europe #EU #CzechRepublic #DariaJulkowska #datainfrastructure #EuropeanConference #innovativetherapies #prague #raredisease
https://www.europesays.com/europe/67977/